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INTRODUCTION 
Cancer, a most dreadful disease and a major cause of 
deaths worldwide occurs due to malignant growth of 
body cells that start growing beyond their usual 
boundaries because of some biochemical or physical 
damage to the normal cells. As per the data of World 
Health Organization, cancer is the second leading cause 
of death after Heart diseases. Out of the various types of 
cancers, Breast cancer is widely prevalent amongst the 
elderly females and is the third leading cause of cancer 
deaths in the United States. In 2014, more than 2 lakh 
breast cancer cases were reported which accounted for 
14% of all new cancer cases while around 40,000 deaths 
accounting for 6.8% of all cancer deaths. Breast cancer 
is usually treated with surgery, which may be followed 
by chemotherapy or radiation therapy, or both. Various 
chemotherapeutic agents such as Docetaxel, Paclitaxel, 
Cisplatin, Carboplatin, Vinorelbine, Capecitabine, 
Gemcitabine etc are used alone or in combination for 
treatment of breast cancer. Most of these are 
administered as intravenous injections needing 
hospitalization leading to poor patient compliance, 
discomfort and possibility of infections. The advent of 
orally effective chemotherapeutic agents such as 
Capacitabine has led to improved patient compliance 
because of possibility of self administration and no 
requirement of hospitalization. This leads to significant 
cost savings, both in terms of treatment costs and lost 
wages incurred by patient and family during physician 
visits
1.
 Capecitabine, an orally-
administered chemotherapeutic agent is a prodrug, that 
is enzymatically converted to active 5-fluorouracil in the 
tumor, where it inhibits DNA synthesis and slows down 
growth of tumor tissue
2
 Capecitabine is completely 
absorbed from the gastrointestinal tract having almost 
100% bioavailability, but it’s very short plasma half life 
(0.85 hours) leads to its rapid elimination from the body 
necessitating its frequent administration. In order to 
achieve the Cmax of 3-5 mg/L, it needs to be 
administered at a very high dose of 1250 mg/m
2
. 
Commercially, it is available as a film coated tablet 
dosage form at two different strengths viz.150 mg and 
500mg. The dosage frequency is 3-6 tablets twice a day 
depending on the body surface area. Such a high 
frequency and dose leads to serious side effects like 
hand and foot syndrome, vomiting, pain in stomach, 
fever or infection leading to poor patient compliance. 
Capacitabine is absorbed throughout the gastrointestinal 
tract. However, it gets degraded in the acidic 
environment of the stomach necessitating the avoidance 
of its exposure to the gastric environment. Design of a 
formulation which could protect capecitabine from 
degradation in stomach and release the drug in 
controlled manner in the intestine would thus lead to 
reduction in the dose and dosing frequency resulting in 
decreased side effects and dose related toxicity. 
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ABSTRACT 
The aim of the present investigation was to formulate and evaluate controlled release beads containing capecitabine in order 
to decrease the dosing frequency. The beads were prepared using sodium alginate and chitosan by ionotropic gelation 
method. The concentrations of the polymers were optimized to obtain the spherical beads with sufficient integrity. The drug 
loaded beads were characterized for entrapment efficiency, size, shape, morphology, swelling index, mucoadhesion and in-
vitro drug release and in-vitro cytotoxicity study. The prepared beads had spherical shape with smooth surface and 
improved micromeritic properties. The entrapment efficiency was found to be 58%, swelling index was 60% and they 
exhibited mucoadhesion to the intestinal tissue for more than 6 hours. The in-vitro drug release studies indicated that the 
beads were able to give zero order controlled release for a period of 6 hours.  
Key Words: Capecitabine, Chitosan, Sodium alginate, Ionotropic gelation 
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Different strategies such as incorporation of matrix 
forming polymers
3
, coating
4
, microsphere
5
 and 
microcapsule
6
 based formulations have been used for 
controlling the release rate of the entrapped drug. 
Controlled release microspheres with use of polymers 
have been reported for capecitabine
7
. Manufacturing of 
microspheres is a complicated process requiring high 
energy stirrers. Beads, on the other hand, are much 
simpler to manufacture. Natural polymers such as 
sodium alginate and chitosan are highly effective in 
controlling the drug release. The use of bioadhesive 
polymers results in a prolonged intestinal retention and 
the swelling causes a formation of a matrix and a 
diffusional path for the drug to be released resulting in 
controlled release. 
Beads are small, solid and free flowing particulate carrie
rs containing dispersed drug particles either in solution 
or crystalline form. Numerous anticancer drugs have 
been incorporated into beads like doxorubicin
8
, 
irinotecan
9
, 5-flourouracil
10
, paclitaxel
11
.  
Thus, the aim of the present investigation was to prepare 
controlled release mucoadhesive beads for capecitabine 
in order to protect it from stomach environment and 
release the drug in controlled manner in the intestine so 
that the frequency of administration is decreased 
resulting in increased patient compliance and reduced 
side effects.  
MATERIALS AND METHODS 
Capecitabine was kindly gifted by Dishman Pvt ltd. 
(Ahmedabad, India). Sodium alginate and calcium 
chloride were purchased from SD Fine chemicals 
(India). Pepsin (1:1000), pancreatin and pectinase 
enzymes were procured from Himedia. Chitosan was 
kindly gifted by Mahtani Chitosan Pvt ltd (India). All 
other materials and solvents were of analytical reagent 
grade.  
PREPARATION OF BEADS 
The concentrations of sodium alginate and calcium 
chloride were optimized by preliminary experimentation 
in which blank beads were prepared using varying 
concentrations. The concentrations which yielded 
spherical beads having sufficient integrity were selected 
for preparing drug loaded beads. The composition of the 
various batches along with the observation is shown in 
Table 1. Drug loaded chitosan-alginate beads were 
prepared by ionotropic gelation method
12
. The following 
solutions were made separately: Solution A-Accurately 
weighed quantities of sodium alginate (3%w/v-450 mg) 
and  
capecitabine were dissolved in 15 ml de-ionized water 
by continuous stirring for 30 minutes using a magnetic 
stirrer. Solution B: Accurately weighed quantity of 
calcium chloride (5%w/v) was dissolved in 35 ml de-
ionized water. To this solution, 10ml of solution 
containing chitosan (dissolved in 2% glacial acetic acid) 
with pH adjusted to 4.5±1 was added. Solution A was 
then extruded dropwise into solution B through 
hypodermic syringe with needle (20G) and stirred for 15 
minutes at 50rpm using magnetic stirrer. This led to 
ionotropic gelation of sodium alginate in the form of 
beads. Stirring was continued for 30 minutes for 
completion of the gelation. The beads were then filtered 
using a whatman filter paper and air dried overnight. 
Various batches where prepared by increasing 
concentrations of drug and chitosan as described in table 
2.  The optimized batch was selected and crosslinked by 
glutaraldehyde vapors. The beads were spread uniformly 
in a petridish and kept in a desiccators containing 
glutaraldehyde at the bottom. The beads were exposed to 
the glutaraldehyde vapours for 24 hours.  
 
         Table 1: Optimization of sodium alginate and calcium chloride concentrations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Batch code Calcium chloride 
(%w/v) 
Sodium alginate 
(%w/v) 
Observation 
T1 1% 1% Beads not formed 
T2  3% Fragile beads 
T3  5% Difficult to inject 
T4 2% 1% Fragile beads 
T5  3% Fragile beads 
T6  4% No spherical shape 
T7 3% 1% Fragile beads 
T8  3% Fragile beads 
T9  4% No spherical shape 
T10 4% 1% No spherical shape 
T11  3% No spherical shape 
T12 5% 1% Nearly spherical shape 
T13  2% Nearly spherical shape 
T14  3% Spherical shape 
T15  4% Spherical shape 
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Table 2:  Optimization of capecitabine and Chitosan concentration 
     
Batch 
Amount of  
Drug (mg) 
Chitosan(%) Yield 
(%) 
Drug loading 
(%w/w) 
%Entrapment  
Efficiency* 
C1 500 1% 31.38 65 38.97±1.27 
C2 700 1% 43.24 64.35 45.81±0.66 
C3 700 2% 45.92 77.26 58.34±1.49 
C4 800 2% 47.88 69.53 52.02±1.37 
*Values are expressed as mean±S.D(n=3) 
 
EVALUATION OF BEADS 
%Yield 
The prepared beads were weighed using a calibrated 
weighing balance and the % yield was calculated using 
the following equation: 
% yield= W/T, where 
W= weight of the beads 
T= Total weight of sodium alginate and capecitabine 
taken 
Drug loading and entrapment efficiency 
Accurately weighed beads (10 mg) were transferred to a 
beaker containing 10 ml Phosphate buffer pH 6.8 and 
the mixture was allowed to stand for 24 hours. The 
contents of the beaker were stirred for 1-2 hours using a 
magnetic stirrer for complete breakage of the beads, 
followed by filtration using whatman filter paper. The 
amount of capecitabine(x) in 10 mg beads was then 
estimated in the filtrate by measuring the absorbance at 
239.5 nm using U.V.-visible spectrophotometer. Drug 
loading and Entrapment efficiency was then calculated 
by following formulae:  
Drug loading (%w/w) = 10x 
% Entrapment efficiency=( x /T)*100 
Where, x = Actual quantity of drug present in beads 
T = Theoretical quantity of drug added during 
preparation 
Micromeritic properties 
The size of beads was determined using optical 
microscopy technique. The beads were spread uniformly 
on a glass slide and observed under microscope. The 
size of 50 beads from each batch was determined using a 
calibrated eye piece micrometer and average was 
calculated. Angle of repose was measured by fixed base 
cone method. Bulk and tapped densities as measures of 
pack-ability of beads were measured using a 5 ml 
graduated cylinder. 1 gm of sample was added in the 
cylinder and volume occupied by sample was noted and 
bulk density was calculated.  The cylinder was tapped 
100 times and volume occupied was again measured to 
calculate tapped density. 
Bulk density = (weight of sample / volume occupied by 
sample before tapping)                         
Tapped density= (weight of sample/ sample occupied by 
sample after tapping)                          
Carr’s index and Hausner’s ratio were also calculated as 
measures of powder flow properties using the following 
equations: 
Carr’s index= (Tapped density – Bulk density) x 100 
              Tapped density 
Hausner’s ratio= (Tapped density / Bulk density)                                                                
SIZE, SHAPE AND SURFACE MORPHOLOGY 
The beads were analyzed microscopically under digital 
microscope (Nikon digital sight, DS-Fi20) to study their 
size and shape. The size of the beads was determined by 
using a calibrated eye piece micrometer. The surface 
morphology of beads was studied using scanning 
electron microscopy (JSM-5610LV, JEOL, Japan). For 
this, samples were attached to sample stubs, silver 
coating was done and then viewed using an accelerating 
voltage at the magnification of 15000X. 
SWELLING INDEX 
Accurately weighed 50mg of beads were taken in a 
beaker containing 10 ml of phosphate buffer pH 6.8 and 
allowed to stand at room temperature for 6 hr. The 
excess liquid adhered to the surface of the beads was 
removed by blotting with filter paper and the swollen 
beads were weighed. Each experiment was carried out in 
triplicate. The swelling index of the beads was 
calculated by using the formula
13
:
 
 
Where, Wi= Weight of the beads after swelling 
   Wt= Initial weight of dried beads 
 
MUCOADHESIVITY TEST
14
 
The mucoadhesivity test was carried out using rat 
intestinal mucosa. All the experimental procedures were 
approved by the Institutional Animal Ethics Committee 
(IAEC) of The Maharaja Sayajirao University of Baroda 
and were in accordance with the Committee for Purpose 
of Control and Supervision of Experiments on Animals 
(CPCSEA), Ministry of Social Justice and 
Empowerment, Government of India. One rat was 
sacrificed and the mucosa was removed and cut into 
pieces (2 x 2 cm) and rinsed with phosphate buffer pH 
6.8. Pieces of wet rat intestinal mucosa were mounted 
onto glass slides with acrylate glue. 50 beads were 
counted and spread uniformly over the surface of wet 
mucosa. A glass slide was connected with a support and 
was hung on the arm of a USP tablet disintegration test 
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apparatus (Figure 1).  The disintegrating test apparatus 
was operated such that the tissue specimen was given 
regular up and down movements in the beaker 
containing alkaline phosphate buffer pH 6.8. The 
temperature was maintained at 37±5
°
C throughout the 
study.  The numbers of beads still adhering to the tissue 
were counted at the end of 6 hours . % Mucoadhesion 
was calculated by following formula: 
 
 
 
Figure 1: Experimental setup for mucoadhesivity test 
 
IN-VITRO DISSOLUTION STUDIES 
The dissolution studies were carried out using USP XII 
dissolution apparatus type I(basket type) at 100 rpm and 
37±0.5°C. The beads equivalent to 200 mg of drug were 
filled in to enteric coated hard gelatin capsules and 
placed in basket separately. The dissolution medium 
(500 ml) was simulated gastric fluid (SGF pH 1.2) for 
the first 2 h, followed by simulated intestinal fluid (SIF 
pH 6.8) for the next 5 h. 5 ml samples were withdrawn 
at specified time intervals and was replaced immediately 
with an equal volume of fresh medium. Samples were 
suitably diluted and analyzed at 239.5 nm UV-
Spectrophotometer (Shimadzu 1700). All the tests were 
carried out in triplicate. The dissolution study of 
marketed formulation Xeloda-500mg tablet was carried 
out using USP dissolution apparatus II (paddle) at 100 
rpm and 37±0.5°C.  
DRUG-EXCIPIENT COMPATIBILITY STUDIES 
The compatibility of Capecitabine with the excipients 
was confirmed by DSC and FTIR studies. The DSC 
thermograms of Capecitabine, Chitosan, Sodium 
alginate, Calcium chloride and the optimized  Beads 
formulation were recorded using Differential Scanning 
Calorimeter DSC-70, Shimadzu; between 30-300°C at a 
heating rate of 10.00 °C/min with constant nitrogen flow 
of 50.0 mL/min. The FTIR spectra of moisture free 
powdered samples of drug, excipients, drug containing 
beads and blank beads(without drug) were recorded 
using Bruker-αt, FTIR spectrophotometer, Japan; The 
samples were mixed with potassium bromide and 
compressed into a pellet before recording the spectra.  
IN-VITRO CYTOTOXICITY STUDIES 
15
 
The anticancer potential of the Capecitabine beads was 
evaluated and compared with its marketed tablet 
(Xeloda®, Roche Inc., Philippines) using the MTT 
based cytotoxic assay on the HT29 colorectal cancer 
cells. The MTT assay involves colorimetric estimation 
of purple colored formazan developed via reduction of 
yellow colored MTT dye by mitochondrial 
dehydrogenase within living cells and thereby, gives a 
direct estimate of number of viable cells. Briefly, 5 x 10
3
 
cells/ml in their exponential growth phase were plated in 
96-well flat-bottom tissue culture plates and incubated at 
37°C, 5% CO2 in an incubator for 24 hr to allow the 
cells to adhere and grow as a monolayer. Concurrently, 
optimized formulation of Capecitabine beads and 
marketed Xeloda® tablet (amount equivalent to 400 mg 
drug) were incubated in simulated body fluids in the 
same way as adapted for in vitro drug release study and 
5ml samples were withdrawn at 1 hr interval starting 
from zero time for the estimation of Capecitabine 
concentration and its cytotoxicity. In the well plates, 
when a monolayer was formed the supernatant was 
removed, the monolayer washed once with phosphate 
buffer saline at pH 7.4 and 100µL of above mentioned 
samples were added to cells in well plate. The plate was 
then incubated at 37°C and 5 % CO2 for 4 hr. At the end 
of the exposure period, the medium was removed from 
all the wells, and the wells were washed with phosphate 
buffer saline at pH 7.4. Then 50 µL of MTT dye 
solution (1 mg/mL) was added to all of wells and 
incubated for 4 hr. After 4 hr, the plate was taken out 
and the medium along with the MTT was removed from 
the wells without disturbing the formazan crystals. Cell 
lysis and solubilization of formazan crystals was done 
by adding 200 μL of DMSO to all of the wells and their 
absorbance were measured using a microplate reader at 
a wavelength of 540 nm. 
STABILITY STUDY 
The optimized batch was filled into hard gelatin enteric 
coated capsule and kept in the stability chamber under 
conditions of 25 ±2°C, 60% RH ±5% and at accelerated 
conditions of 40 ±2°C, 75% RH ±5%. At intervals of 0, 
1, 2 and 3 months, formulations were characterized for 
% drug content and in-vitro drug dissolution using the 
procedure mentioned earlier. 
RESULT AND DISCUSSION 
The present investigation aimed to prepare 
mucoadhesive beads for controlled release of 
Capecitabine. The selection of the polymers was done 
based on the preliminary experimentation and literature 
survey. The main characteristics required were the 
bioadhesive nature and ability of control the release rate 
along with biodegradability, non-toxicity and economic 
viability. In recent years, the use of natural polymers as 
carriers has been increased as they are biocompatible, 
biodegradable and easily available at reasonable cost. 
Ionotropic gelation is a simple technique used for 
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preparing sodium alginate beads, which have the 
property of swelling in aqueous media and controlling 
the release rate of entrapped drug
16
.When an aqueous 
solution of sodium alginate is dropped into counter-ions 
solution (calcium), the metallic calcium ions rapidly 
diffuse into alginate solution droplets because of their 
smaller size than polymeric ions, and bind to 
unoccupied binding sites on these polymers to form 
calcium alginate beads by ion-exchange. The results of 
the experiments for optimization of the sodium alginate 
and calcium chloride concentration are shown in table 1. 
It is evident that at lower concentration of Calcium 
chloride, the beads are not formed. This might be 
because of the insufficient gelation due to availability of 
lower amounts of counter ions. The optimum calcium 
chloride concentration was found to be 5%. In case of 
sodium alginate concentration, lower concentrations 
resulted in fragile and irregular shaped beads whereas 
too high concentration of 5% was difficult to inject 
because of high viscosity. Thus, 3% sodium alginate 
concentration was considered to be optimum which 
resulted in spherical shaped beads with sufficient 
integrity. When capecitabine loaded beads were 
prepared using 3% sodium alginate and 5% calcium 
chloride, very low entrapment efficiency was obtained. 
This was because of the tendency of capecitabine, a 
highly water soluble drug to leach out in the aqueous 
calcium chloride solution. This observation was 
confirmed by estimating the drug in the external phase. 
Additional use of chitosan in chitosan-alginate beads has 
already been recognized as stabilizing the “egg-box” 
structure and thereby reducing the problem of drug 
leaching during bead preparation
17
. Thus, varying 
concentrations of chitosan were added to the calcium 
chloride solution in order to increase the entrapment 
efficiency. It is evident from the table 2 that on 
increasing the chitosan concentration, the drug loading 
and %EE increased significantly. This may be due to the 
fact that higher chitosan concentration results in the 
formation of a denser matrix structure that probably 
decreases the loss of drug to the curing medium. In 
addition, electrostatic attraction between the negatively 
charged capecitabine and the positively charged chitosan 
also becomes stronger, promoting the drug entrapment. 
Thus, the optimized chitosan concentration and the 
amount of capecitabine to be added during the 
preparation were 2% and 700 mg respectively. Further 
increase in capecitabine amount to 800 mg led to a 
decrease in entrapment efficiency maybe because of 
availability of higher amount of drug to be leached out 
in the external aqueous medium. As the capecitabine 
loading concentration increased, more capecitabine 
molecules were just electrostatically adsorbed onto the 
surface of chitosan and were easily separated from beads 
resulting in a decrease in the entrapment efficiency.  The 
results of the micromeritic studies are shown in table 3. 
 
Table 3: Micromeritic properties of pure drug and beads 
Batch Angle of 
repose (θ) 
Bulk density 
(gm/cm
3
) 
Tapped density 
(gm/cm
3
) 
Hausner’s ratio Carr’s index 
(%) 
Average particle 
size (µm) 
Pure 
drug 
49.68 
±0.02 
0.389 
±0.006 
0.591 
±0.005 
1.52 
±0.03 
34.08 
±1.14 
- 
C1 22.85 
±0.03 
0.611 
±0.002 
0.723 
±0.003 
1.18 
±0.01 
15.57 
±0.50 
1121.35 
C2 23.25 
±0.03 
0.638 
±0.003 
0.752 
±0.006 
1.18 
±0.02 
15.07 
±1.12 
1126.27 
C3 27.57 
±0.05 
0.656 
±0.004 
0.785 
±0.003 
1.20 
±0.01 
16.47 
±0.47 
1388.36 
C4 27.97 
±0.04 
0.675 
±0.004 
0.835 
±0.004 
1.24 
±0.01 
19.17 
±0.84 
1381.65 
 
The values of the different micromeritic parameters 
indicate the poor flow properties of pure drug while all 
the bead formulations showed acceptable flow 
properties and compression characteristics. The 
improved flow properties might be due to the spherical 
shape and smooth surface of the beads which show 
minimum resistance to flow. An increase in chitosan 
concentration led to an increase in particle size. This 
result is expected since capecitabine carried negative 
charge and electro statically interacted with chitosan, 
which would promote formation of beads through ionic 
cross-linking. Thus, as the chitosan concentration was 
increased; the particle size was also increased. The 
optimized batch had a mean size of around 1.3 mm. The 
SEM images are shown in figures 2. 
These images confirmed that the formulated beads were 
spherical in shape with a relatively smooth surface 
texture. Moreover, in the SEM images, no drug crystals 
were found on bead surface, which indicate that the drug 
particles were present in the form of a finely dispersed 
state in the polymeric matrix of beads. Moreover the 
size obtained through SEM images is in concurrence 
with that obtained by optical microscopy. The 
glutaraldehyde crosslinking does not significantly affect 
the size of the beads. The in-vitro drug release studies 
were done for all the batches as well as glutaraldehyde 
crosslinked batch C3. Crosslinking was done using 
vapors of glutaraldehyde in order to minimize its residue 
and thereby toxicity in the final product. Sustained and 
controlled drug release may be achieved by selecting a 
polymer with the proper molecular weight and swelling 
properties.
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Figure 2: a) SEM of sodium alginate-chitosan beads of 
capecitabine (Without crosslinked) 
b) SEM of sodium alginate-chitosan beads of 
capecitabine (crosslinked) 
 
Upon coming in contact with gastric fluid, the polymer 
imbibes water and swells. The extensive swelling of 
these polymers is a result of the presence of physical–
chemical crosslinks in the hydrophilic polymer network. 
These cross-links prevent the dissolution of the polymer 
and thus maintain the physical integrity of the dosage 
form. A balance between the extent and duration of 
swelling is maintained by the degree of crosslinking 
between the polymeric chains. A high degree of 
crosslinking retards the swelling ability of the system 
and maintains its physical integrity for a prolonged 
period. On the other hand, a low degree of cross-linking 
results in extensive swelling followed by the rapid 
dissolution of the polymer. An optimum amount of 
cross-linking is required to maintain a balance between 
swelling and dissolution
18
. Swelling index was 
determined by measuring the extent of swelling of beads 
in the given buffer. Here, swelling index was evaluated 
in terms of weight. All the batches exhibited very high 
values of swelling index as can be seen from table 4.   
 Table 4: Swelling Index and % Mucoadhesion of beads 
Batch Swelling Index % Mucoadhesion 
C1 2015.17±1.97 34 
C2 2022.50±2.71 32 
C3 1203.70±2.19 60 
C4 1209.60±1.57 60 
 
It was found that an increase in chitosan concentration in 
beads resulted in decreased swelling. The reason may be 
that in swelling process, the Ca
2+
 ions present in the 
polymannuronate units of alginate, are exchanged with 
Na 
+
 ions present in the buffer solution, which ultimately 
causes chain relaxation and enhances gel formation or 
swelling
19
. The adhesive property of the carrier towards 
the mucus membrane lining the intestine is reported to 
increase the residence time of the delivery system in the 
intestine ultimately leading to controlled release. 
Mucoadhesivity test was done and the results are shown 
in table 4.  It can be seen from the results that the highest 
mucoadhesion of 60% was found in batch C3 and C4 
containing 2% of chitosan at the end of 6 hours. 
Mucoadhesion of 32 % was observed with beads 
containing 1% of Chitosan. Thus, mucoadhesivity 
increased when chitosan concentration was increased. 
The basis of mucoadhesion could be described in terms 
of electronic theory: electron transfer occurred between 
the positively charged chitosan and sodium alginate 
polymers of the formulation and the negatively charged 
mucus glycoprotein network. This led to the formation 
of an electrical double layer that resulted in adherence to 
beads for a longer time.  
 
 
Figure 3:  a)  In-vitro release of capecitabine beads 
b)  Comparative release profile with marketed preparation 
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Moreover, increased polymer concentrations resulted in 
increased viscosity of gel that was formed and 
ultimately led to higher adhesion. This helps in the 
release of drug in a sustained manner before the beads 
were eroded away. There was no significant effect of 
drug loading on the mucoadhesivity. 
It can be seen from and figure 3 that there was almost no 
drug release in first two hours because the beads were 
filled in enteric capsules and the release medium used 
was simulated gastric fluid. There was no significant 
effect of chitosan concentration on the drug release as 
evidenced by the results for batch C2 and C3. However, 
crosslinking with glutaraldehyde led to a significant 
decrease in the drug release. Glutaraldehyde 
crosslinking leads to a formation of dense matrix and 
hence retardation of drug release. The comparison of the 
release profile of the developed formulation C3 and the 
marketed tablet formulation is shown in figure 3. In the 
case of the marketed tablet preparation, almost entire 
amount of the drug released within an hour. The rapid 
release necessitates frequent administration of the 
marketed tablet preparation. The bead formulation, on 
the other hand is able to control the release rate for more 
than 7 hours leading to a possibility of reduction of the 
dosing frequency. Model fitting of the drug release data 
is shown in table 5.  
                            
Table 5: Model fitting of in-vitro release studies 
 
 
 
 
 
The drug is release by first order as indicated by the 
high r
2 
value.  The chemical compatibility between 
capecitabine and other formulation components 
(excipients) was ensured using DSC and FTIR studies.  
Thermal analysis of pure capecitabine and capecitabine-
loaded beads were conducted using DSC. These 
experiments measure the heat gain or loss from chemical 
or physical changes within a sample as a function of 
temperature. The DSC thermograms of the various 
samples are shown in figure 4. 
 
 
Figure 4:  DSC thermograms of   a) capecitabine   b) Chitosan   c) Sodium alginate d) optimized batch C3 
 
The thermogram of capecitabine showed a sharp 
endothermic peak at 121.9°C, which nearly 
corresponded to the melting point of capecitabine (116–
118°C). This peak was absent in both the thermograms 
of drug loaded beads formulation, confirming complete 
entrapment of the drug in polymer matrix. The FTIR 
spectra of the different samples are shown in figure 5.  
Formulation 
code 
First 
order 
Zero 
order 
Higuchi Hixon-
Crowel 
Korsmeyer-Peppas 
r
2
 N 
C3 0.9396 0.8024 0.7055 0.7485 0.8913 2.2124 
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Figure 5: FTIR spectra of   a) Capecitabine   b) Chitosan   c) Sodium alginate d) optimized batch C3 
 
In the spectrum of capecitabine, there are sharp peaks at 
1757, 1333, 1242, and 1117 cm
-1
 corresponding to C=O 
stretching vibrations (pyrimidine carbonyl), C-N 
bending vibrations, N-H bending vibrations (tetrahydro 
furan), and C-F stretching vibrations respectively. These 
peaks were found in drug-loaded chitosan-sodium 
alginate beads. This confirms that no chemical 
interaction was found between the drug and polymers, 
thus confirming drug compatibility with these 
excipients. The result of the in-vitro cytotoxicity studies 
is shown in table 6.  
                                                
Table 6: Invitro cytotoxicity studies 
Time(h) Batch C3 Xeloda tablet 
 Conc. 
(μg/mL) 
%cell viability Conc. 
(μg/mL) 
%cell 
viability 
0 0.00 0.00 0.00 0.00 
1 0.00 100.12±1.26 0.00 0.00 
2 0.00 101.23±1.48 0.00 0.00 
3 34.96 97.07±0.98 444 5.32±0.91 
4 40.028 95.34±2.58 996 6.76±2.44 
5 62.922 94.45±2.27 - - 
6 158.24 76.88±2.76 - - 
7 274.788 56.65±1.24 - - 
8 -  - - 
9 -  - - 
 
Blank beads did not show any cytotoxicity against HT-
29 cells indicating its safe use as a drug delivery system. 
The beads formulation showed cytotoxicity against HT-
29 cells. Hence, the formulation can be effectively tested 
for its anticancer property. Xeloda tablet showed total 
drug release within first hour itself at SIF pH 6.8. The 
percentage cell viability was reduced up to 2% meaning 
98% cell death occurred in HT-29 cells. Chitosan-
Sodium alginate beads showed slower controlled drug 
release with 56% cell viability at the end of 7 hr 
meaning that 44 % cell death occurred at this time. 
Hence, in spite of slower drug release, the formulation 
showed good cytotoxicity. The results of stability 
studies at 25°C, 60% RH and 40°C, 75% RH of the 
optimized formulation (batch C3) are shown in figure 6.  
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Figure 6:    Stability Study- Effect of temperature and relative humidity on 
a) % drug content of chitosan-sodium alginate beads batch C3 
b) % drug release of  chitosan-sodium alginate beads batch C3 
 
There was no significant change in drug content and drug 
release for a period of three months at both the storage 
conditions indicating the stability of the formulation, which 
is expected because of the solid dosage form.  
CONCLUSION 
Controlled release mucoadhesive beads of Capecitabine 
were successfully prepared by ionic gelation which is a 
very simple technique. The beads were spherical in shape 
and had a smooth surface with very good flow properties 
and compressibility. The in-vitro dissolution studies 
indicated sustained release from the beads for more than 7 
hours. The beads had good swelling property and 
mucoadhesivity and were found to have excellent stability, 
both at 40°C and 25°C. Extended research involving 
pharmacokinetic and pharmacodynamic studies in suitable 
animal models is expected to prove this formulation a 
superior to the presently available marketed formulation.  
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